

## ASX Announcement

### Imugene Webinar and Q&A: Imugene Licenses CAR T Directed OV Therapy for Solid Tumours

---

**Sydney, Australia, 18 May 2021:** Imugene Ltd (ASX:IMU), a clinical stage immuno-oncology company is pleased to announce it will hold an investor webinar and Q&A for all shareholders and interested parties following the release of “Imugene Licenses CD19 Oncolytic Virus from City Of Hope to Turn CAR T Therapy Against Solid Tumours”.

Managing Director and CEO Leslie Chong will be joined by Dr Yuman Fong & Dr Saul Priceman from City of Hope to discuss the announcement at 10am AEST tomorrow, Wednesday 19 May 2021.

Please register for the webinar at:

[https://us02web.zoom.us/webinar/register/WN\\_3MnBYj03SXuJtezpEbcERg](https://us02web.zoom.us/webinar/register/WN_3MnBYj03SXuJtezpEbcERg)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone.

Please note a replay of the webinar will be available at the above-mentioned Zoom link shortly following the conclusion of the live session.

This release has been authorised by the directors of Imugene Limited.

For more information please contact:

Imugene  
Leslie Chong  
Managing Director and Chief Executive Officer  
T: +61 458 040 433  
Follow us on Twitter @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited

## About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited